ArriVent BioPharma (AVBP) Other Operating Expenses (2024 - 2026)

ArriVent BioPharma (AVBP) has 3 years of Other Operating Expenses data on file, last reported at -$2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 7.44% year-over-year to -$2.3 million; the trailing twelve-month figure through Mar 2026 stood at -$8.9 million (down 17.2% YoY), and the FY2025 full-year result was -$8.8 million, down 22.77% from the prior year.
• Other Operating Expenses declined to -$2.3 million in Q1 2026, from -$2.3 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of -$1.5 million in Q4 2024 to a low of -$2.4 million in Q2 2025.
• A 3-year average of -$2.0 million and a median of -$2.1 million in 2024 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 7.37% in 2025, while the deepest fall reached 54.86% in 2025.
• Tracing AVBP's Other Operating Expenses over 3 years: stood at -$1.5 million in 2024, then tumbled by 54.86% to -$2.3 million in 2025, then fell by 2.21% to -$2.3 million in 2026.
• Business Quant data shows AVBP's Other Operating Expenses at -$2.3 million in Q1 2026, -$2.3 million in Q4 2025, and -$1.9 million in Q3 2025.